Process & Analytical Development

Upstream Process Development — development, optimization, characterization, scale-up, and tech transfer of cell culture production processes (cell line evaluation, media/feed strategy, bioreactor operation across batch/fed-batch/perfusion modes) for biopharmaceutical drug substance. Distinct from Downstream/Purification (chromatography, filtration), Analytical Development (assay/method development), Formulation/Drug Product, and Process Analytics focuses; centers specifically on the bioreactor-based cell culture (upstream) unit operations.

Downstream Process Development focuses on the recovery and purification of biological products following cell culture/fermentation — clarification, cell lysis, chromatography (affinity, ion-exchange, multi-modal, SEC, HIC), filtration (TFF, depth, sterile, viral), and continuous/integrated processing. It develops, optimizes, scales up, transfers, and validates purification unit operations to deliver target yield, purity, potency, and consistency. Distinct from Upstream Process Development (cell line/culture and fermentation), Analytical Development (assay/method development and characterization), and Formulation (drug product/stability).

Analytical Development for biologics and small molecules — develops, qualifies, validates and transfers analytical methods (chromatography, mass spectrometry, spectroscopy, CE-SDS, cell-based/ligand-binding potency assays) supporting in-process, release, stability, characterization and comparability testing from early development through licensure. Distinct from sibling Process Development focuses, which own upstream/downstream process design and scale-up; this focus owns the analytical control strategy, CQA risk assessment, method lifecycle and CMC analytical content rather than the manufacturing process itself.

Upstream Process Development — development, optimization, characterization, scale-up, and tech transfer of cell culture production processes (cell line evaluation, media/feed strategy, bioreactor operation across batch/fed-batch/perfusion modes) for biopharmaceutical drug substance. Distinct from Downstream/Purification (chromatography, filtration), Analytical Development (assay/method development), Formulation/Drug Product, and Process Analytics focuses; centers specifically on the bioreactor-based cell culture (upstream) unit operations.

Analytical Development for biologics and small molecules — develops, qualifies, validates and transfers analytical methods (chromatography, mass spectrometry, spectroscopy, CE-SDS, cell-based/ligand-binding potency assays) supporting in-process, release, stability, characterization and comparability testing from early development through licensure. Distinct from sibling Process Development focuses, which own upstream/downstream process design and scale-up; this focus owns the analytical control strategy, CQA risk assessment, method lifecycle and CMC analytical content rather than the manufacturing process itself.

Downstream Process Development focuses on the recovery and purification of biological products following cell culture/fermentation — clarification, cell lysis, chromatography (affinity, ion-exchange, multi-modal, SEC, HIC), filtration (TFF, depth, sterile, viral), and continuous/integrated processing. It develops, optimizes, scales up, transfers, and validates purification unit operations to deliver target yield, purity, potency, and consistency. Distinct from Upstream Process Development (cell line/culture and fermentation), Analytical Development (assay/method development and characterization), and Formulation (drug product/stability).

Upstream Process Development — development, optimization, characterization, scale-up, and tech transfer of cell culture production processes (cell line evaluation, media/feed strategy, bioreactor operation across batch/fed-batch/perfusion modes) for biopharmaceutical drug substance. Distinct from Downstream/Purification (chromatography, filtration), Analytical Development (assay/method development), Formulation/Drug Product, and Process Analytics focuses; centers specifically on the bioreactor-based cell culture (upstream) unit operations.

Analytical Development for biologics and small molecules — develops, qualifies, validates and transfers analytical methods (chromatography, mass spectrometry, spectroscopy, CE-SDS, cell-based/ligand-binding potency assays) supporting in-process, release, stability, characterization and comparability testing from early development through licensure. Distinct from sibling Process Development focuses, which own upstream/downstream process design and scale-up; this focus owns the analytical control strategy, CQA risk assessment, method lifecycle and CMC analytical content rather than the manufacturing process itself.

Downstream Process Development focuses on the recovery and purification of biological products following cell culture/fermentation — clarification, cell lysis, chromatography (affinity, ion-exchange, multi-modal, SEC, HIC), filtration (TFF, depth, sterile, viral), and continuous/integrated processing. It develops, optimizes, scales up, transfers, and validates purification unit operations to deliver target yield, purity, potency, and consistency. Distinct from Upstream Process Development (cell line/culture and fermentation), Analytical Development (assay/method development and characterization), and Formulation (drug product/stability).

Downstream Process Development focuses on the recovery and purification of biological products following cell culture/fermentation — clarification, cell lysis, chromatography (affinity, ion-exchange, multi-modal, SEC, HIC), filtration (TFF, depth, sterile, viral), and continuous/integrated processing. It develops, optimizes, scales up, transfers, and validates purification unit operations to deliver target yield, purity, potency, and consistency. Distinct from Upstream Process Development (cell line/culture and fermentation), Analytical Development (assay/method development and characterization), and Formulation (drug product/stability).

Upstream Process Development — development, optimization, characterization, scale-up, and tech transfer of cell culture production processes (cell line evaluation, media/feed strategy, bioreactor operation across batch/fed-batch/perfusion modes) for biopharmaceutical drug substance. Distinct from Downstream/Purification (chromatography, filtration), Analytical Development (assay/method development), Formulation/Drug Product, and Process Analytics focuses; centers specifically on the bioreactor-based cell culture (upstream) unit operations.

Analytical Development for biologics and small molecules — develops, qualifies, validates and transfers analytical methods (chromatography, mass spectrometry, spectroscopy, CE-SDS, cell-based/ligand-binding potency assays) supporting in-process, release, stability, characterization and comparability testing from early development through licensure. Distinct from sibling Process Development focuses, which own upstream/downstream process design and scale-up; this focus owns the analytical control strategy, CQA risk assessment, method lifecycle and CMC analytical content rather than the manufacturing process itself.

Upstream Process Development — development, optimization, characterization, scale-up, and tech transfer of cell culture production processes (cell line evaluation, media/feed strategy, bioreactor operation across batch/fed-batch/perfusion modes) for biopharmaceutical drug substance. Distinct from Downstream/Purification (chromatography, filtration), Analytical Development (assay/method development), Formulation/Drug Product, and Process Analytics focuses; centers specifically on the bioreactor-based cell culture (upstream) unit operations.

Downstream Process Development focuses on the recovery and purification of biological products following cell culture/fermentation — clarification, cell lysis, chromatography (affinity, ion-exchange, multi-modal, SEC, HIC), filtration (TFF, depth, sterile, viral), and continuous/integrated processing. It develops, optimizes, scales up, transfers, and validates purification unit operations to deliver target yield, purity, potency, and consistency. Distinct from Upstream Process Development (cell line/culture and fermentation), Analytical Development (assay/method development and characterization), and Formulation (drug product/stability).

Analytical Development for biologics and small molecules — develops, qualifies, validates and transfers analytical methods (chromatography, mass spectrometry, spectroscopy, CE-SDS, cell-based/ligand-binding potency assays) supporting in-process, release, stability, characterization and comparability testing from early development through licensure. Distinct from sibling Process Development focuses, which own upstream/downstream process design and scale-up; this focus owns the analytical control strategy, CQA risk assessment, method lifecycle and CMC analytical content rather than the manufacturing process itself.

Analytical Development for biologics and small molecules — develops, qualifies, validates and transfers analytical methods (chromatography, mass spectrometry, spectroscopy, CE-SDS, cell-based/ligand-binding potency assays) supporting in-process, release, stability, characterization and comparability testing from early development through licensure. Distinct from sibling Process Development focuses, which own upstream/downstream process design and scale-up; this focus owns the analytical control strategy, CQA risk assessment, method lifecycle and CMC analytical content rather than the manufacturing process itself.

Upstream Process Development — development, optimization, characterization, scale-up, and tech transfer of cell culture production processes (cell line evaluation, media/feed strategy, bioreactor operation across batch/fed-batch/perfusion modes) for biopharmaceutical drug substance. Distinct from Downstream/Purification (chromatography, filtration), Analytical Development (assay/method development), Formulation/Drug Product, and Process Analytics focuses; centers specifically on the bioreactor-based cell culture (upstream) unit operations.

Downstream Process Development focuses on the recovery and purification of biological products following cell culture/fermentation — clarification, cell lysis, chromatography (affinity, ion-exchange, multi-modal, SEC, HIC), filtration (TFF, depth, sterile, viral), and continuous/integrated processing. It develops, optimizes, scales up, transfers, and validates purification unit operations to deliver target yield, purity, potency, and consistency. Distinct from Upstream Process Development (cell line/culture and fermentation), Analytical Development (assay/method development and characterization), and Formulation (drug product/stability).

Analytical Development for biologics and small molecules — develops, qualifies, validates and transfers analytical methods (chromatography, mass spectrometry, spectroscopy, CE-SDS, cell-based/ligand-binding potency assays) supporting in-process, release, stability, characterization and comparability testing from early development through licensure. Distinct from sibling Process Development focuses, which own upstream/downstream process design and scale-up; this focus owns the analytical control strategy, CQA risk assessment, method lifecycle and CMC analytical content rather than the manufacturing process itself.